Final FDA user fee and reform legislation has cleared the House and is set for a Senate vote this week. The legislation incorporates a mix of device provisions drawn from separately passed House and Senate FDA bills, including somewhat controversial language streamlining the device reclassification process.
The compromise bill was the result of weeks of informal meetings between Senate and House staffers to come to agreement on differences between packages approved in the two chambers last...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?